Preparation and administration1

How to mix POTELIGEO

1.Visually inspect drug product solution for particulate matter and discoloration prior to administration. POTELIGEO is a clear to slightly opalescent colorless solution. Do not use the vial if cloudiness, discoloration, or particulates are observed.

2.Calculate the dose (mg/kg) and number of vials of POTELIGEO needed to prepare the infusion solution based on patient weight. Each vial contains 20 mg of POTELIGEO, which is enough for 20 kg of body weight.

3.Aseptically withdraw the required volume of POTELIGEO into the syringe and transfer into an intravenous (IV) baga containing 0.9% Sodium Chloride Injection, USP. The final concentration of the diluted solution should be between 0.1 mg/mL and 3.0 mg/mL.

4.Mix diluted solution by gentle inversion. Do not shake. After preparation, infuse the POTELIGEO solution immediately, or store under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 4 hours from the time of infusion preparation. Do not freeze. Do not shake.

5.Discard any unused portion left in the vial.

Administration

  • Administer infusion solution over at least 1 hour through an IV line containing a sterile, low protein binding, 0.22 micron (or equivalent) in-line filter
  • Do not mix POTELIGEO with other drugs
  • Calculate the dose (mg/kg) and number of vials of POTELIGEO needed to prepare the infusion solution based on patient weight
  • Do not co-administer other drugs through the same IV line
  • Prepared POTELIGEO is a clear to slightly opalescent colorless solution—without particulates

For more information on dosing, see the POTELIGEO Dosing and Administration Guide

Resource for you to use while counseling patients on what to expect during treatment,
see the POTELIGEO Patient Scheduling and Monitoring Treatment Guide

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

SEE LESS

Warnings and Precautions

  • Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
  • Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.
  • Infections: Monitor patients for signs and symptoms of infection and treat promptly.
  • Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.
  • Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

Adverse Reactions

  • The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).
  • You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This website uses cookies to personalize content, save your preferences, and track its performance. By continuing to use this website, you consent to the use of these cookies.
POTELIGEO is a registered trademark of
Kyowa Hakko Kirin Co., Ltd.
© 2019 Kyowa Kirin, Inc. All rights reserved.
PM-US-POT-0042 July 2019